In spite of its wide and beneficial pharmacological potential, resveratrol lags behind other compounds because of its comparatively less impressive pharmacokinetic profile. Resveratrol has very low oral bioavailability and, from a formulation perspective, it has low solubility in water, which leads to its poor absorption upon oral administration. Apart from low aqueous solubility, resveratrol has poor metabolic stability and instability at high pH, and is photosensitive. The pharmacokinetic and formulation-related limitations of resveratrol can be controlled by entrapping the small resveratrol molecule inside highly water-soluble poly(amidoamine) dendrimer nanostructures, which provide spherical architecture and polyvalency at the nanoscale level, thus leading to novel features. Dendrimer architecture is used to entrap resveratrol for enhancement of its solubility and stability in aqueous solution; they can be engineered to control pharmacokinetics and targeting for oral, mucosal, transdermal, or parenteral administration. Dendrimers have the potential to work as excipients with multifunctional capability by enhancing solubility, dissolution, stability, permeability, multiple drug/cosmetic entrapment, controlled delivery, bioavailability, and efficacy of drugs.